Norditropin Nordiflex (Somatropin)

Somatropin, the active ingredient in Norditropin Nordiflex, is a human growth hormone presented as a subcutaneous injectable for use in patients requiring growth hormone therapy. It is indicated for children and adults with growth hormone deficiency, Turner syndrome, Prader‑Willi syndrome, chronic renal insufficiency, and idiopathic short stature, helping to promote normal growth and metabolic function.

GNH USA supplies Norditropin Nordiflex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other global markets.

Norditropin Nordiflex, a recombinant human growth hormone, acts on the growth hormone–IGF‑1 axis to support growth and metabolic processes. - Growth hormone deficiency: promotes linear growth and improves body composition in children and adults lacking endogenous GH. - Turner syndrome: enhances height velocity and final adult stature in girls with this chromosomal disorder. - Prader‑Willi syndrome: supports growth and improves body composition in affected individuals. - Chronic renal insufficiency: aids growth in pediatric patients with renal disease‑related growth failure. - Idiopathic short stature: facilitates increased growth rate in children with unexplained short stature.

Somatropin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort or redness at the injection site. - Headache: transient headache occurring after administration. - Edema: fluid retention leading to swelling of hands or feet. - Joint stiffness: temporary stiffness or arthralgia. - Nausea: occasional feeling of nausea.

Serious or Rare Side Effects: - Intracranial hypertension: signs include persistent headache, visual disturbances, or vomiting. - Hyperglycemia: elevated blood glucose levels, particularly in diabetic patients. - Antibody formation: development of neutralizing antibodies reducing drug efficacy.

When prescribing somatropin, clinicians should consider several precautionary measures to ensure safe use. - Monitor blood glucose: patients with diabetes may experience altered glucose control. - Assess intracranial pressure: watch for symptoms of increased pressure, especially in children. - Evaluate thyroid function: hypothyroidism can affect response to therapy. - Screen for malignancy: use with caution in individuals with active cancer. - Pediatric growth monitoring: regular height and growth velocity assessments are required. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Corticosteroids: may antagonize growth‑promoting effects, reducing treatment benefit. - Antidiabetic agents: somatropin can worsen hyperglycemia, requiring dose adjustments.

Moderate Interactions (Monitor Closely): - Estrogen therapy: may increase IGF‑1 levels, necessitating monitoring. - Thyroid hormone replacement: adjustments may be needed to maintain euthyroid state. - Cyclosporine: may alter somatropin metabolism, requiring careful observation.